The health misinformation crisis is bigger than anyone thought: Most people worldwide believe at least one of 6 common medical myths

A 2026 Edelman survey found 70% of respondents worldwide believe at least one of six debunked health claims, while confidence in finding reliable health answers fell 10 points in a year to 51% and trust in health media is down to 46% globally. The article also highlights rising use of AI in health management, with 35% of respondents using AI and 64% saying an AI-fluent person can match or outperform a trained doctor on at least one task. The piece is primarily a consumer-health and trust narrative, with limited immediate market impact.

Analysis

The key market implication is not “more misinformation,” but a structurally larger addressable market for AI-mediated healthcare. When trust in institutions degrades faster than care access improves, consumers do not wait for system-wide reform; they adopt lower-friction substitutes that feel personalized and nonjudgmental. That creates a durable tailwind for consumer health AI, telehealth triage, symptom-checking, and workflow software that sits between patients and physicians, while pressuring legacy channels that monetize attention rather than resolution.

Second-order effects are likely to show up in reimbursement and utilization patterns before they show up in earnings. If patients increasingly use AI for pre-visit sorting and second opinions, demand should shift toward providers that can absorb higher-intent, better-prepared patients while reducing unnecessary visits; standalone primary care and urgent care networks could see lower conversion on low-acuity traffic. Over 6-18 months, the winners are platforms that can turn “AI as a guide” into compliance, scheduling, and steering into owned care pathways; the losers are generic media brands and ad-supported health content businesses that depend on being the first stop in the information funnel.

The contrarian read is that this is not a pure trust collapse trade — it is partly a normalization of decision delegation. If AI becomes the default interface for health questions, the marginal consumer may not be less informed, just differently informed, which could reduce churn in some chronic-care and pharmacy-adherence workflows. The biggest risk to the AI/health thesis is regulatory backlash after a high-profile adverse event; that would likely compress multiples for consumer-facing health AI names quickly, but would also benefit audited, clinician-supervised platforms over pure-play chat interfaces.

From a portfolio perspective, the near-term catalyst is product disclosure season: management teams will begin highlighting patient-intake automation, prior-auth reduction, and call-center deflection as margin levers. The highest-conviction setup is a barbell: long platforms that own trusted distribution and workflow, short the attention layer that gets disintermediated by AI. If public skepticism worsens over the next 3-6 months, adoption should accelerate faster than reimbursement changes, creating a window where revenue growth outruns headline regulatory risk.

Key Decisions for Investors

• Long HIMS / short META on a 3-6 month horizon: consumer health-specific AI adoption should benefit direct-to-consumer health platforms more than broad social distribution layers; target 1.5-2.0x relative performance if health acquisition costs rise and trust in social search continues to erode.
• Long DOCS into the next 2 quarters: physician-facing workflow is the monetization path if AI becomes the patient front door; upside comes from visit conversion, intake automation, and stronger enterprise retention, with downside limited if AI adoption proves merely incremental.
• Long TDOC vs short AMCX-style health content proxies (or, if unavailable, short a basket of ad-supported health/media names): the thesis is disintermediation of informational content by AI, with 6-12 month margin pressure as traffic shifts away from content discovery.
• Buy 6-12 month call spreads on EDITED health-tech/telehealth leaders after any post-earnings pullback: the market is likely underestimating how quickly ‘AI as second opinion’ converts into paid workflows; prefer structures with defined downside because regulatory headlines can gap risk higher.
• Avoid or hedge pure consumer-facing symptom-checker names without clinical oversight: they may see fast adoption, but they also carry the highest tail-risk from one adverse-event headline or state-level scrutiny.